Abstract 5101
Background
Recent reports suggested gaps in knowledge and misperceptions regarding lung cancer (LC) in the general public and physicians respectively. We aimed to further investigate the topic.
Methods
From February 21st to March 22nd, 2019, two online surveys were led in parallel among French people (n = 6001) and physicians (GP, n = 273; pulmonologists, n = 97; oncologists, n = 67). Questions aimed to assess people’s knowledge about LC prevalence, severity, diagnosis, management and treatments, early screening, as well of social stigma, and also understandings from physicians about public perception.
Results
LC was ranked as the 2nd most feared cancer (n = 1980; 33%) and perceived as very or extremely serious by 96% of people (n = 5760). Half of French people (n = 3360) declared knowing at least one other risk factor than tobacco, and except for asbestos (n = 5220; 87%), other potential risk factors were subjects to low to moderate levels of belief. The general population ranked LC as the 3rd easiest cancer to diagnose among French people (n = 2220; 37%) and 57% (n = 3420) believed that diagnosis was made early after symptoms onset. The general population was not aware of the majority of the symptoms beside blood in the sputum and respiratory symptoms. LC was ranked only the 5th cancer (n = 1260; 21%) among those for which medical progress had been the most substantial, whereas physicians ranked it second (n = 201; 46%). Also the public was not aware of therapeutic progress as immunotherapy. Physicians tended to be more optimistic about actual treatment improvement than the public and for 90% of them (n = 393), systematic screening of at-risk population would have a significant impact on mortality data by LC.
Conclusions
Our study confirms the substantial gaps in LC knowledge from the general public and highlights several venues for improvement of communication and public awareness on LC in France.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J. Cadranel: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boerhinger Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. C. Chouaid: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: GSK; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi Aventis; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen. J.B. Stern: Speaker Bureau / Expert testimony, Fees for presentation in a Medtronic symposium which were donated to our association.: Medtronic. A. Vergnenegre: Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Teva; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Clovis Oncology. C. Cortot: Full / Part-time employment: AstraZeneca. L. Guery: Full / Part-time employment: AstraZeneca. K. Belkhiria: Full / Part-time employment: AstraZeneca. I. De la Porte: Full / Part-time employment: AstraZeneca. M. Urbieta: Full / Part-time employment: AstraZeneca. M. Perol: Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract
3186 - The landscape of immuno-oncology clinical trials in China
Presenter: Dawei Wu
Session: Poster Display session 3
Resources:
Abstract
3468 - Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.
Presenter: Samia Hajem
Session: Poster Display session 3
Resources:
Abstract
3836 - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
Presenter: Wim Meer
Session: Poster Display session 3
Resources:
Abstract
1343 - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
Presenter: Thura Win Htut
Session: Poster Display session 3
Resources:
Abstract
5783 - Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials
Presenter: Guru Sonpavde
Session: Poster Display session 3
Resources:
Abstract
5422 - EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
Presenter: Marie Kostine
Session: Poster Display session 3
Resources:
Abstract
1202 - Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)
Presenter: Shinichi Sasaki
Session: Poster Display session 3
Resources:
Abstract
2749 - Use of Checkpoint Inhibitors (CPI) in Allogeneic Stem Cell Transplant Recipients: An Institutional Experience and A Systemic Review of the Literature
Presenter: Chantal Saberian
Session: Poster Display session 3
Resources:
Abstract
3256 - Deep Learning Radiomics distinguishes intrapulmonary Disease from Metastases in Immunotherapy-treated Melanoma Patients
Presenter: Thi Dan Linh Nguyen-Kim
Session: Poster Display session 3
Resources:
Abstract